Analysts Offer Predictions for Crispr Therapeutics AG’s Q4 2019 Earnings (NASDAQ:CRSP)

Crispr Therapeutics AG (NASDAQ:CRSP) – Analysts at Oppenheimer issued their Q4 2019 earnings per share (EPS) estimates for Crispr Therapeutics in a research report issued on Tuesday, July 30th. Oppenheimer analyst S. Tuerkcan anticipates that the company will post earnings of ($1.09) per share for the quarter. Oppenheimer also issued estimates for Crispr Therapeutics’ FY2020 earnings at ($4.11) EPS, FY2021 earnings at ($4.19) EPS, FY2022 earnings at ($4.27) EPS and FY2023 earnings at ($1.17) EPS.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, July 29th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.84). The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $47.57 million. Crispr Therapeutics had a negative return on equity of 50.55% and a negative net margin of 15,136.56%. The firm’s revenue was down 70.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.82) EPS.

Several other equities analysts have also commented on CRSP. Roth Capital upped their price target on shares of Crispr Therapeutics from $50.00 to $65.00 in a research report on Tuesday. BTIG Research upped their price objective on shares of Crispr Therapeutics from $51.00 to $59.00 and gave the stock a “positive” rating in a report on Tuesday. Zacks Investment Research raised shares of Crispr Therapeutics from a “hold” rating to a “strong-buy” rating and set a $55.00 price objective for the company in a report on Tuesday, July 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $62.00 price objective on shares of Crispr Therapeutics in a report on Wednesday. Finally, Evercore ISI began coverage on shares of Crispr Therapeutics in a report on Thursday, April 11th. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $58.00.

Crispr Therapeutics stock opened at $50.69 on Thursday. The business’s 50-day moving average price is $47.62. The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of -14.74 and a beta of 3.11. The company has a quick ratio of 15.84, a current ratio of 15.84 and a debt-to-equity ratio of 0.08. Crispr Therapeutics has a one year low of $22.22 and a one year high of $59.00.

Large investors have recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC increased its position in Crispr Therapeutics by 71.4% in the first quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock worth $26,000 after buying an additional 302 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new stake in Crispr Therapeutics in the second quarter worth about $41,000. Lenox Wealth Management Inc. lifted its holdings in Crispr Therapeutics by 1,731.7% in the first quarter. Lenox Wealth Management Inc. now owns 2,198 shares of the company’s stock worth $79,000 after purchasing an additional 2,078 shares during the period. Dubuque Bank & Trust Co. lifted its holdings in Crispr Therapeutics by 101.6% in the first quarter. Dubuque Bank & Trust Co. now owns 2,873 shares of the company’s stock worth $103,000 after purchasing an additional 1,448 shares during the period. Finally, Aperio Group LLC acquired a new stake in Crispr Therapeutics in the second quarter worth about $153,000. 48.92% of the stock is owned by institutional investors and hedge funds.

In related news, insider Lawrence Otto Klein sold 20,000 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $50.02, for a total transaction of $1,000,400.00. Following the completion of the sale, the insider now directly owns 31,579 shares of the company’s stock, valued at $1,579,581.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Rodger Novak sold 50,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $50.00, for a total value of $2,500,000.00. Following the sale, the president now directly owns 848,007 shares of the company’s stock, valued at $42,400,350. The disclosure for this sale can be found here. Insiders have sold 140,000 shares of company stock valued at $6,670,400 over the last ninety days. 21.40% of the stock is currently owned by company insiders.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: Put Option

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.